Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Senzime AB ( (SE:SEZI) ) has shared an update.
Senzime AB has won a significant contract with a leading Ivy League university hospital system in the US, covering an initial installation of 60 next‑generation TetraGraph neuromuscular monitoring systems and anticipated annual usage of more than 10,000 disposable sensors at full rollout. The deal deepens Senzime’s penetration of the influential US academic hospital segment, underscores its positioning as a leader in neuromuscular monitoring for anesthesiology, and is likely to support recurring revenue growth through consumable sensor sales while reinforcing the company’s profile as a provider of technology that aligns with evolving patient safety guidelines and cost-efficiency demands in perioperative care.
The most recent analyst rating on (SE:SEZI) stock is a Sell with a SEK4.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime AB is a Swedish medical device company focused on precision-based perioperative monitoring systems that enhance patient safety, improve outcomes and reduce costs during surgery. Founded in 1999 and headquartered in Uppsala, the company’s flagship TetraGraph system provides real-time neuromuscular transmission monitoring to guide accurate dosing of paralytic and reversal drugs, and is used in thousands of operating rooms worldwide across university, veterans’, public and private hospitals. Senzime is listed on Nasdaq Stockholm and cross-traded on the US OTCQX market.
Average Trading Volume: 272,781
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK809.7M
For detailed information about SEZI stock, go to TipRanks’ Stock Analysis page.